Not investment advice. Origin reports data from public SEC filings with cryptographic provenance. No buy/sell/hold recommendations. Past performance does not indicate future results.
## VNRX Collapses to $0.27 — NYSE Delisting Now Effectively Certain as Filing Signals Undergo Dramatic Structural Shift
From the inaugural observation at $1.13 on July 20 to $0.2749 on September 16, VNRX has lost approximately 76% of its value in under two months. The $0.04 buffer flagged as urgent in the July 23 observation has long since evaporated — the stock has now traded well below the $1.00 NYSE continued listing threshold for an extended period, making a formal delisting notice, if not already received, a near-certainty under NYSE rules requiring 30 consecutive trading days below $1.00 to trigger compliance action. At $0.2749, the company would need a roughly 264% recovery to regain listing compliance, an extraordinary threshold for a pre-revenue diagnostics company with zero transcript coverage and no fundamental anchor. The filing signal structure has undergone a dramatic and analytically significant shift. Where the original 10-K showed a 7:1 risk-to-strategy ratio (71 risk_factor matches against 10 ai_adoption, 5 strategic_event), the current data shows ai_adoption surging to 67 and 54 matches, and strategic_event expanding to 56, 52, and 48 matches — while risk_factor holds at 70-71. This compression of the risk-to-strategy ratio toward near-parity suggests either an amended filing, a new filing period, or substantially revised disclosure language emphasizing AI integration and strategic activity. That shift warrants direct examination of the underlying filing text. Watch for: formal NYSE delisting notice or OTC transfer announcement; whether the elevated ai_adoption and strategic_event language reflects a concrete commercial partnership or licensing event that has not yet reached transcript capture; and whether the 360 all-time Origin queries reflect any informed accumulation or purely distressed retail activity.
## VNRX Collapses to $0.27 — NYSE Delisting Now a Near-Certainty as Stock Trades 73% Below Compliance Threshold
The deterioration flagged across prior observations has accelerated catastrophically. VNRX closed at $0.2749 on September 16, 2026 — a 74% decline from Origin's opening coverage price of $1.13 on July 21, and a 74% plunge from the $1.04 level that triggered the urgent delisting flag on July 23. The stock is now trading at roughly 27 cents on the dollar relative to the NYSE's $1.00 minimum bid requirement. At this depth, the compliance clock — typically a 30-day notification followed by a 180-day cure period — is almost certainly already running, if not exhausted. A reverse split or transfer to OTC markets are the most probable near-term structural outcomes absent an extraordinary catalyst. The filing signal structure remains frozen in its original configuration: 71 risk factor matches against 10 ai_adoption and 5 strategic_event hits, with zero earnings transcripts captured across the entire coverage period. That absence of transcript data is now more than a data gap — it reflects a company that has provided no public fundamental anchoring through this entire price collapse. Origin's query count has grown from 191 to 325 all-time, suggesting retail interest persisting even as price disintegrates, which is characteristic of distressed micro-cap speculation rather than fundamental accumulation. Watch for: any formal NYSE non-compliance notification or cure plan disclosure; whether management pursues a reverse stock split to restore listing eligibility; any 8-K filing capturing strategic events that might explain or contextualize the price action; and whether OTC transfer occurs before a formal cure window expires.
## VNRX Breaches $1.00 Decisively — Delisting Risk Now Active as Stock Collapses 54% From Coverage Open
The structural risk flagged at coverage open on July 21 ($1.13) and escalated on July 23 ($1.04, with just $0.04 of buffer remaining) has now fully materialized. VNRX closed at $0.4741 on August 18, 2026 — a 58% decline from the inaugural observation price and a decisive breach of the NYSE $1.00 continued listing threshold. This is no longer a proximity watch; this is an active compliance event. NYSE rules typically require a 30-day average closing price below $1.00 to trigger a formal deficiency notice, but at $0.47 — nearly 53 cents below threshold — the trajectory makes a notice increasingly unavoidable unless a sharp reversal occurs. The market cap, already sub-$100M at coverage open, has compressed further in lockstep. Origin AI query volume has grown from 191 at coverage open to 314 all-time, a 64% increase — suggesting elevated retail attention precisely as the price deteriorates, a pattern consistent with speculative interest in distressed micro-cap names rather than fundamental-driven accumulation. The filing signal structure remains static: 71 risk factor matches against 10 ai_adoption and 5 strategic_event hits, and zero earnings transcripts have been captured across all six observations, leaving cash runway entirely unquantifiable from available data. Watch for: any formal NYSE deficiency notice, which would trigger a 6-month cure period and likely accelerate institutional exit; any 8-K disclosures around financing, reverse split authorization, or partnership announcements that could serve as catalysts; and whether transcript capture becomes available to assess burn rate against the current price environment.
## VNRX Breaches $1.00 With Force — $0.4741 Print Signals Structural Deterioration Beyond Listing Risk
The $1.00 delisting threshold flagged as "urgent" in the July 23 observation has not merely been breached — it has been obliterated. VNRX now trades at $0.4741 as of August 18, 2026, representing a 54.4% decline from the July 22 close of $1.04 and a 58.1% collapse from Origin's opening coverage price of $1.13. This is no longer a listing-threshold watch; this is a company trading at less than half its NYSE minimum, suggesting either a formal deficiency notice has already been issued or is imminent. At sub-$0.50, the stock enters territory where reverse split speculation typically accelerates, and where institutional participation becomes structurally constrained by mandate floors. The fundamental picture remains unchanged in the worst possible way: zero earnings transcripts captured across all five observations, meaning there is still no auditable cash runway figure available through Origin's data layer. The filing signal ratio — 71 risk factors against 10 ai_adoption mentions and 5 strategic_event hits — looks increasingly prophetic. Query volume has grown from 191 to 303 all-time, a 59% increase, suggesting retail interest is spiking on the collapse rather than on any positive catalyst, a pattern consistent with distressed-name speculation rather than fundamental accumulation. Watch for: any SEC Form 8-K disclosing NYSE non-compliance notification; reverse split authorization language appearing in proxy filings; and whether any strategic_event signals in the 10-K reference partnership structures that could provide non-dilutive capital. Transcript capture remains the single most important data gap.
The deterioration flagged across prior observations has now moved from warning to crisis. VNRX printed $0.4741 on August 18, 2026 — a 54% collapse from the $1.04 level observed on July 22, and a 58% decline from Origin's opening coverage price of $1.13. The $0.04 buffer to the NYSE $1.00 listing threshold that triggered urgency in the second observation has been entirely consumed; the stock now trades at less than half that threshold. Under NYSE rules, a stock closing below $1.00 for 30 consecutive trading days triggers a formal deficiency notice, initiating a compliance cure period typically running 180 days. Given the trajectory, it is probable that notice has already been issued or is imminent, making the compliance clock a primary structural variable to track. The underlying filing signal ratio — 71 risk_factor matches against 10 ai_adoption and 5 strategic_event matches — now reads less as a disclosure posture and more as a predictive document. Zero transcripts captured across four observations means there is still no fundamental anchor: no visibility into cash runway, burn rate, or whether any commercial partnership activity has materialized from the strategic_event language in the 10-K. The jump from 191 to 294 all-time AI queries on Origin (+54%) suggests retail attention is increasing, likely driven by price volatility rather than fundamental discovery. Watch for: any formal NYSE deficiency notice filing via 8-K; cash position disclosure that would indicate months of runway remaining; and whether any strategic_event language in the 10-K maps to an announced partnership that could serve as a stabilizing catalyst.
## VNRX Collapses to $0.50 — NYSE Delisting Now a Structural Certainty Absent Intervention
The deterioration flagged in prior observations has accelerated dramatically. VNRX has fallen to $0.50 as of August 17, 2026 — a 51.9% decline from the $1.04 level noted in the July 23 observation, and a 55.8% collapse from Origin's opening coverage price of $1.13. The stock has been trading below the NYSE's $1.00 minimum bid price threshold continuously, meaning the exchange's 30-trading-day compliance clock is likely already running, if not already exhausted. At $0.50, the company now requires a 100% price appreciation simply to regain listing compliance — a mathematical threshold that, for a pre-revenue clinical-stage diagnostics company with zero captured earnings transcripts and no visible cash runway data, represents an extremely high bar without a material catalyst. The filing signal structure remains static: 71 risk_factor matches against 10 ai_adoption and 5 strategic_event matches. That 7:1 risk-to-strategy ratio, identified at inception as a baseline concern, now reads as prescient. Origin AI query volume has grown modestly to 281 all-time — a 47% increase since coverage opened — suggesting retail interest is tracking the price decline rather than any fundamental development. Watch for: a formal NYSE non-compliance notice disclosure, which would trigger a public 6-K or 8-K filing and begin the cure period clock; any announced reverse stock split, which is the most common mechanism to restore listing compliance; or the appearance of a first earnings transcript, which would finally allow cash runway assessment and determine whether the company retains operational viability independent of its listing status.
## VNRX Touches $1.00 — Delisting Threshold Breached on Closing Basis, Structural Risk Now Acute
The deterioration flagged across two prior observations has now materialized into a closing price of exactly $1.00 on July 24, 2026 — a 3.85% decline from the $1.04 print observed July 22. Origin opened coverage at $1.13 on July 21; the stock has shed 11.5% in three trading sessions. The $0.04 buffer identified in the prior observation is now exhausted. NYSE listing standards typically trigger a deficiency notice when a stock closes below $1.00 for 30 consecutive trading days — today's print at precisely $1.00 does not yet constitute a violation, but the margin for error is now zero. Any single closing print below $1.00 starts that 30-day clock. The filing signal structure remains structurally unchanged: 71 risk_factor matches against 10 ai_adoption and 5 strategic_event matches across the 10-K. With zero transcripts captured and no fundamental data anchor available on cash runway, burn rate, or near-term catalysts, price action is operating in an information vacuum — a condition that historically amplifies downside volatility in sub-$100M clinical-stage names. The marginal uptick in Origin AI queries (194 all-time, up from 191 two days ago) suggests minimal incremental institutional or retail engagement. Watch for: any closing print below $1.00 triggering NYSE deficiency monitoring; whether the company issues any press release or 8-K addressing listing status or announces a capital raise; and whether strategic_event filing language maps to any near-term pipeline readout that could provide a fundamental catalyst.
## VNRX Slips to $1.04 — Delisting Threshold Now Just $0.04 Away as Coverage Risk Flag Escalates
One trading day after Origin opened coverage at $1.13, VNRX has declined to $1.04 on July 22, 2026 — a 7.96% single-session move that compresses the NYSE continued listing buffer to a critical $0.04. The prior observation flagged the $1.00 threshold as a structural watch; that watch has now become urgent. At this proximity, any intraday breach of $1.00 — even without a closing violation — tends to attract heightened scrutiny and can accelerate retail selling pressure in thinly capitalized names. The market cap remains sub-$100M, and with zero earnings transcripts captured, there is no fundamental anchor available to assess cash runway or near-term catalysts that might stabilize price action. The filing signal structure remains unchanged: 71 risk_factor matches against 10 ai_adoption and 5 strategic_event matches across the 10-K. That 7:1 risk-to-strategy ratio, paired with a rapidly deteriorating price, creates a compounding concern — the document architecture reflects a company acutely aware of its vulnerability, and the market appears to be pricing that awareness in real time. AI query volume on Origin ticked up marginally to 193 (from 191), suggesting modest incremental interest but no surge that would indicate institutional re-rating activity. Watch for: whether VNRX closes below $1.00 on any session this week, triggering NYSE compliance clock mechanics; any 8-K filing disclosing a capital raise, reverse split authorization, or partnership announcement that could serve as a price stabilizer; and whether transcript capture becomes possible, which remains the single largest analytical gap in this coverage.
## VolitionRx Opens Coverage at $1.13 With Elevated Risk Profile and Nascent AI Signal
This marks the inaugural observation for VNRX on Origin. VolitionRx trades at $1.13 on the NYSE as of July 20, 2026, with a market capitalization registering below $1B — effectively sub-$100M territory consistent with a pre-revenue clinical-stage diagnostics company. The 10-K filing structure reveals a heavily risk-weighted document: 71 risk factor matches against just 10 ai_adoption matches and 5 strategic_event matches. That ratio — roughly 7:1 risk-to-strategy — is a meaningful signal. Companies at this stage frequently load risk disclosures, but the density here warrants attention as a baseline measure. The 191 all-time AI queries on Origin suggests a modest but present retail and analyst interest in the name, despite zero earnings transcripts captured, which limits fundamental triangulation considerably. The ai_adoption signal appearing across multiple filing sections (10 matches fragmented into counts of 2, 2, 1, 1) suggests the language is distributed rather than concentrated — likely defensive or aspirational mentions rather than operationally embedded AI deployment. The strategic_event hits (5 total, split 5 and 2) may point to partnership language or pipeline milestones worth isolating in the full filing text. Watch for: any transcript capture that would allow revenue trajectory and cash runway analysis; whether strategic_event disclosures reference commercial partnerships or licensing activity for their nucleosome-based liquid biopsy platform; and whether the stock holds above $1.00, the critical NYSE continued listing threshold given current price proximity. The $0.13 buffer to delisting risk is a near-term structural watch.